# Jain Dataset - ELISA-based Fragments (SSOT)
# Source: test_datasets/jain/processed/jain_with_private_elisa_FULL.csv
# Labeling: ELISA flags (0→specific, 1-3→mild, ≥4→non-specific)
# Distribution: 94 specific / 22 non-specific / 21 mild
# Generated: 2025-11-06
# Script: preprocessing/jain/step3_extract_fragments.py
id,sequence,label,elisa_flags,source
abituzumab,QVQLQQSGGELAKPGASVKVSCKASMHWVRQAPGQGLEWIGYEYNEIFRDKATMTTDTSTSTAYMELSSLRSEDTAVYYCWGQGTTVTVSS,0.0,0,jain2017_pnas
abrilumab,QVQLVQSGAEVKKPGASVKVSCKVSIHWVRQAPGKGLEWMGGIYAQKFQGRVTMTEDTSTDTAYMELSSLKSEDTAVYYCWGQGTLVTVSS,0.0,0,jain2017_pnas
adalimumab,EVQLVESGGGLVQPGRSLRLSCAASMHWVRQAPGKGLEWVSADYADSVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCWGQGTLVTVSS,0.0,0,jain2017_pnas
alemtuzumab,QVQLQESGPGLVRPSQTLSLTCTVSMNWVRQPPGRGLEWIGFEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCWGQGSLVTVSS,0.0,0,jain2017_pnas
alirocumab,EVQLVESGGGLVQPGGSLRLSCAASMNWVRQAPGKGLDWVSTNYADSVKGRFIISRDSSKHTLYLQMNSLRAEDTAVYYCWGRGTLVTVSS,0.0,0,jain2017_pnas
anifrolumab,EVQLVQSGAEVKKPGESLKISCKGSIAWVRQMPGKGLESMGIRYSPSFQGQVTISADKSITTAYLQWSSLKASDTAMYYCWGRGTLVTVSS,0.0,0,jain2017_pnas
atezolizumab,EVQLVESGGGLVQPGGSLRLSCAASIHWVRQAPGKGLEWVAWYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCWGQGTLVTVSS,0.0,0,jain2017_pnas
bapineuzumab,EVQLLESGGGLVQPGGSLRLSCAASMSWVRQAPGKGLEWVASYYSDNVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCWGQGTLVTVSS,0.0,0,jain2017_pnas
basiliximab,QVQLQQSGTVLARPGASVKMSCKASMHWIKQRPGQGLEWIGASYNQKFEGKAKLTAVTSASTAYMELSSLTHEDSAVYYCWGQGTTLTVSS,0.0,0,jain2017_pnas
bavituximab,EVQLQQSGPELEKPGASVKLSCKASMNWVKQSHGKSLEWIGHSYNQKFRGKATLTVDKSSSTAYMQLKSLTSEDSAVYYCWGAGTTVTVSS,0.0,0,jain2017_pnas
belimumab,QVQLQQSGAEVKKPGSSVRVSCKASINWVRQAPGQGLEWMGGKYSQNFQGRVAITADESTGTASMELSSLRSEDTAVYYCWGRGTMVTVSS,1.0,6,jain2017_pnas
benralizumab,EVQLVQSGAEVKKPGASVKVSCKASIHWVRQRPGQGLAWMGYKYNERFKGKVTITSDRSTSTVYMELSSLRSEDTAVYLCWGQGTLVTVSS,0.0,0,jain2017_pnas
bevacizumab,EVQLVESGGGLVQPGGSLRLSCAASMNWVRQAPGKGLEWVGWTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCWGQGTLVTVSS,0.0,0,jain2017_pnas
bimagrumab,QVQLVQSGAEVKKPGASVKVSCKASINWVRQAPGQGLEWMGTSYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCWGQGTLVTVSS,0.0,0,jain2017_pnas
blosozumab,QVQLVQSGAEVKKPGASVKVSCKVSQHWVRQAPGKGLEWMGWEYASKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCWGQGTTVTVSS,1.0,6,jain2017_pnas
bococizumab,QVQLVQSGAEVKKPGASVKVSCKASMHWVRQAPGQGLEWMGENYNEKFKSRVTMTRDTSTSTVYMELSSLRSEDTAVYYCWGQGTTVTVSS,1.0,6,jain2017_pnas
brentuximab,QIQLQQSGPEVVKPGASVKISCKASITWVKQKPGQGLEWIGWKYNEKFKGKATLTVDTSSSTAFMQLSSLTSEDTAVYFCWGQGTQVTVSA,,3,jain2017_pnas
briakinumab,QVQLVESGGGVVQPGRSLRLSCAASMHWVRQAPGKGLEWVAFYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCWGQGTMVTVSS,1.0,4,jain2017_pnas
brodalumab,QVQLVQSGAEVKKPGASVKVSCKASISWVRQAPGQGLEWMGWNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCWGQGTLVTVSS,,1,jain2017_pnas
canakinumab,QVQLVESGGGVVQPGRSLRLSCAASMNWVRQAPGKGLEWVAIYYADSVKGRFTISRDNSKNTLYLQMNGLRAEDTAVYYCWGQGTLVTVSS,0.0,0,jain2017_pnas
carlumab,QVQLVQSGAEVKKPGSSVKVSCKASISWVRQAPGQGLEWMGGNYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCWGQGTLVTVSS,1.0,4,jain2017_pnas
certolizumab,EVQLVESGGGLVQPGGSLRLSCAASMNWVRQAPGKGLEWMGWIYADSVKGRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCWGQGTLVTVSS,0.0,0,jain2017_pnas
cetuximab,QVQLKQSGPGLVQPSQSLSITCTVSVHWVRQSPGKGLEWLGVDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCWGQGTLVTVSA,0.0,0,jain2017_pnas
cixutumumab,EVQLVQSGAEVKKPGSSVKVSCKASISWVRQAPGQGLEWMGGNYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCWGKGTTVTVSS,1.0,6,jain2017_pnas
clazakizumab,EVQLVESGGGLVQPGGSLRLSCAASVTWVRQAPGKGLEWVGIAYATSAIGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCWGQGTLVTVSS,0.0,0,jain2017_pnas
codrituzumab,QVQLVQSGAEVKKPGASVKVSCKASMHWVRQAPGQGLEWMGAAYSQKFKGRVTLTADKSTSTAYMELSSLTSEDTAVYYCWGQGTLVTVSS,1.0,6,jain2017_pnas
crenezumab,EVQLVESGGGLVQPGGSLRLSCAASMSWVRQAPGKGLELVASYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCWGQGTTVTVSS,0.0,0,jain2017_pnas
dacetuzumab,EVQLVESGGGLVQPGGSLRLSCAASIHWVRQAPGKGLEWVARSYNQKFKGRFTLSVDNSKNTAYLQMNSLRAEDTAVYYCWGQGTLVTVSS,0.0,0,jain2017_pnas
daclizumab,QVQLVQSGAEVKKPGSSVKVSCKASMHWVRQAPGQGLEWIGYEYNQKFKDKATITADESTNTAYMELSSLRSEDTAVYYCWGQGTLVTVSS,,1,jain2017_pnas
dalotuzumab,QVQLQESGPGLVKPSETLSLTCTVSWNWIRQPPGKGLEWIGYNYKPSLKDRVTISRDTSKNQFSLKLSSVTAADTAVYYCWGQGTLVTVSS,1.0,5,jain2017_pnas
daratumumab,EVQLLESGGGLVQPGGSLRLSCAVSMSWVRQAPGKGLEWVSAYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCWGQGTLVTVSS,0.0,0,jain2017_pnas
denosumab,EVQLLESGGGLVQPGGSLRLSCAASMSWVRQAPGKGLEWVSGYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCWGQGTLVTVSS,1.0,5,jain2017_pnas
dinutuximab,EVQLLQSGPELEKPGASVMISCKASMNWVRQNIGKSLEWIGASYNQKFKGRATLTVDKSSSTAYMHLKSLTSEDSAVYYCWGQGTSVTVSS,0.0,0,jain2017_pnas
drozitumab,EVQLVQSGGGVERPGGSLRLSCAASMSWVRQAPGKGLEWVSGGYADSVKGRVTISRDNAKNSLYLQMNSLRAEDTAVYYCWGKGTTVTVSS,0.0,0,jain2017_pnas
duligotuzumab,EVQLVESGGGLVQPGGSLRLSCAASIHWVRQAPGKGLEWVGEDYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCWGQGTLVTVSS,1.0,6,jain2017_pnas
dupilumab,EVQLVESGGGLEQPGGSLRLSCAGSMTWVRQAPGKGLEWVSSYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCWGQGTTVTVSS,1.0,5,jain2017_pnas
eculizumab,QVQLVQSGAEVKKPGASVKVSCKASIQWVRQAPGQGLEWMGEEYTENFKDRVTMTRDTSTSTVYMELSSLRSEDTAVYYCWGQGTLVTVSS,0.0,0,jain2017_pnas
efalizumab,EVQLVESGGGLVQPGGSLRLSCAASMNWVRQAPGKGLEWVGMRYNQKFKDRFTISVDKSKNTLYLQMNSLRAEDTAVYYCWGQGTLVTVSS,0.0,0,jain2017_pnas
eldelumab,QMQLVESGGGVVQPGRSLRLSCTASMHWVRQAPGKGLEWVAVFYVDSVKGRFTISRDNSKNTLYLEMNSLRAEDTAIYYCWGQGTTVTVSS,0.0,0,jain2017_pnas
elotuzumab,EVQLVESGGGLVQPGGSLRLSCAASMSWVRQAPGKGLEWIGENYAPSLKDKFIISRDNAKNSLYLQMNSLRAEDTAVYYCWGQGTLVTVSS,0.0,0,jain2017_pnas
emibetuzumab,QVQLVQSGAEVKKPGASVKVSCKASMHWVRQAPGQGLEWMGRTYNQKFEGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCWGQGTTVTVSS,1.0,6,jain2017_pnas
enokizumab,QVQLVQSGAEVKKPGSSVKVSCKASIEWVRQAPGQGLEWMGENPNEKFKGRVTITADESTSTAYMELSSLRSEDTAVYYCWGQGTLVTVSS,0.0,0,jain2017_pnas
epratuzumab,QVQLVQSGAEVKKPGSSVKVSCKASLHWVRQAPGQGLEWIGYEYNQNFKDKATITADESTNTAYMELSSLRSEDTAFYFCWGQGTTVTVSS,,1,jain2017_pnas
etrolizumab,EVQLVESGGGLVQPGGSLRLSCAASWGWVRQAPGKGLEWVGYSYNPSLKSRFTISRDTSKNTFYLQMNSLRAEDTAVYYCWGQGTLVTVSS,,2,jain2017_pnas
evolocumab,EVQLVQSGAEVKKPGASVKVSCKASISWVRQAPGQGLEWMGWNYAQKLQGRGTMTTDPSTSTAYMELRSLRSDDTAVYYCWGQGTTVTVSS,,2,jain2017_pnas
farletuzumab,EVQLVESGGGVVQPGRSLRLSCSASLSWVRQAPGKGLEWVAMYYADSVKGRFAISRDNAKNTLFLQMDSLRPEDTGVYFCWGQGTPVTVSS,0.0,0,jain2017_pnas
fasinumab,QVQLVQSGAEVKKPGASVKVSCKVSIHWVRQAPGKGLEWMGGIYAQKFQGRVTMTEDTSTDTAYMELTSLRSEDTAVYYCWGQGTLVTVSS,0.0,0,jain2017_pnas
fezakinumab,QVQLVQSGAEVKKPGASVKVSCKASMHWVRQAPGQGLEWVGWFYAQKFRGRVTMTRDTSISTAYMELSRLRSDDTAVYYCWGRGTLVTVSS,0.0,0,jain2017_pnas
ficlatuzumab,QVQLVQPGAEVKKPGTSVKLSCKASMHWVRQAPGQGLEWIGENYNQKFQGRATLTVDKSTSTAYMELSSLRSEDTAVYYCWGQGTLLTVSS,0.0,0,jain2017_pnas
figitumumab,EVQLLESGGGLVQPGGSLRLSCTASMNWVRQAPGKGLEWVSAFYADSVKGRFTISRDNSRTTLYLQMNSLRAEDTAVYYCWGQGTTVTVSS,,3,jain2017_pnas
fletikumab,QVQLVQSGAEVKRPGASVKVSCKASIHWVRQAPGQRLEWMGWQYSQNFQDRVSITRDTSASTAYMELISLRSEDTAVYYCWGQGTTVTVSS,0.0,0,jain2017_pnas
foralumab,QVQLVESGGGVVQPGRSLRLSCAASMHWVRQAPGKGLEWVAVYYVDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCWGRGTLVTVSS,,2,jain2017_pnas
fresolimumab,QVQLVQSGAEVKKPGSSVKVSCKASISWVRQAPGQGLEWMGGNYAQRFKGRVTITADESTSTTYMELSSLRSEDTAVYYCWGQGTLVTVSS,0.0,0,jain2017_pnas
fulranumab,EVQLVESGGGLVQPGGSLRLSCAASMNWVRQAPGKGLEWVSYFYADSVKGRFTISRDNAKNSLYLQMDSLRDEDTAMYYCWGQGILVTVSS,,1,jain2017_pnas
galiximab,QVQLQESGPGLVKPSETLSLTCAVSWGWIRQPPGKGLEWIGSYYNPSLKSQVTISTDTSKNQFSLKLNSMTAADTAVYYCWGPGVLVTVSS,0.0,0,jain2017_pnas
ganitumab,QVQLQESGPGLVKPSGTLSLTCAVSWSWVRQPPGKGLEWIGENYNPSLKSRVTISVDKSKNQFSLKLSSVTAADTAVYYCWGQGTMVTVSS,0.0,0,jain2017_pnas
gantenerumab,QVELVESGGGLVQPGGSLRLSCAASMSWVRQAPGKGLEWVSAYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCWGQGTLVTVSS,1.0,6,jain2017_pnas
gemtuzumab,EVQLVQSGAEVKKPGSSVKVSCKASIHWVRQAPGQSLEWIGYDYNQKFKNRATLTVDNPTNTAYMELSSLRSEDTAFYYCWGQGTLVTVSS,0.0,0,jain2017_pnas
gevokizumab,QVQLQESGPGLVKPSQTLSLTCSFSVGWIRQPSGKGLEWLAHSYNPSLKSRLTISKDTSKNQVSLKITSVTAADTAVYFCWGQGTLVTVSS,0.0,0,jain2017_pnas
girentuximab,DVKLVESGGGLVKLGGSLKLSCAASMSWVRQTPEKRLELVAAYYLDTVKGRFTISRDNAKNTLYLQMSSLKSEDTALFYCWGQGTSVTVSS,0.0,0,jain2017_pnas
glembatumumab,QVQLQESGPGLVKPSQTLSLTCTVSWSWIRHHPGKGLEWIGYYSNPSLKSRVTISVDTSKNQFSLTLSSVTAADTAVYYCWGQGTLVTVSS,0.0,0,jain2017_pnas
golimumab,QVQLVESGGGVVQPGRSLRLSCAASMHWVRQAPGNGLEWVAFKYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCWGQGTTVTVSS,,1,jain2017_pnas
guselkumab,EVQLVQSGAEVKKPGESLKISCKGSIGWVRQMPGKGLEWMGIRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCWGQGTLVTVSS,,1,jain2017_pnas
ibalizumab,QVQLQQSGPEVVKPGASVKMSCKASIHWVRQKPGQGLDWIGYDYDEKFKGKATLTSDTSTSTAYMELSSLRSEDTAVYYCWGQGTLVTVSS,0.0,0,jain2017_pnas
imgatuzumab,QVQLVQSGAEVKKPGSSVKVSCKASIHWVRQAPGQGLEWMGYTYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCWGQGTTVTVSS,1.0,5,jain2017_pnas
infliximab,EVKLEESGGGLVQPGGSMKLSCVASMNWVRQSPEKGLEWVAEHYAESVKGRFTISRDDSKSAVYLQMTDLRTEDTGVYYCWGQGTTLTVSS,0.0,0,jain2017_pnas
inotuzumab,EVQLVQSGAEVKKPGASVKVSCKASIHWVRQAPGQGLEWIGGTYRRKFQGRVTMTADTSTSTVYMELSSLRSEDTAVYYCWGQGTLVTVSS,,3,jain2017_pnas
ipilimumab,QVQLVESGGGVVQPGRSLRLSCAASMHWVRQAPGKGLEWVTFYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAIYYCWGQGTLVTVSS,0.0,0,jain2017_pnas
ixekizumab,QVQLVQSGAEVKKPGSSVKVSCKASIHWVRQAPGQGLEWMGVDYNQRFKGRVTITADESTSTAYMELSSLRSEDTAVYYCWGQGTLVTVSS,1.0,6,jain2017_pnas
lampalizumab,EVQLVQSGPELKKPGASVKVSCKASMNWVRQAPGQGLEWMGWTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCWGQGTLVTVSS,0.0,0,jain2017_pnas
lebrikizumab,QVTLRESGPALVKPTQTLTLTCTVSVNWIRQPPGKALEWLAMVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATYYCWGQGSLVTVSS,0.0,0,jain2017_pnas
lenzilumab,QVQLVQSGAEVKKPGASVKVSCKASIHWVRQAPGQRLEWMGWKYSQKFQGRVTITRDTSASTAYMELSSLRSEDTAVYYCWGQGTLVTVSS,1.0,6,jain2017_pnas
lintuzumab,QVQLVQSGAEVKKPGSSVKVSCKASMHWVRQAPGQGLEWIGYGYNQKFKSKATITADESTNTAYMELSSLRSEDTAVYYCWGQGTLVTVSS,0.0,0,jain2017_pnas
lirilumab,QVQLVQSGAEVKKPGSSVKVSCKASISWVRQAPGQGLEWMGGNYAQKFQGRVTITADESTSTAYMELSSLRSDDTAVYYCWGQGTTVTVSS,0.0,0,jain2017_pnas
lumiliximab,EVQLVESGGGLAKPGGSLRLSCAASMDWVRQAPGQGLEWVSRWYADSVKGRFTISRENANNTLFLQMNSLRAEDTAVYYCWGQGVLVTVSS,0.0,0,jain2017_pnas
matuzumab,QVQLVQSGAEVKKPGASVKVSCKASMHWVRQAPGQGLEWIGENYNEKFKSKATMTVDTSTNTAYMELSSLRSEDTAVYYCWGQGTLVTVSS,0.0,0,jain2017_pnas
mavrilimumab,QVQLVQSGAEVKKPGASVKVSCKVSIHWVRQAPGKGLEWMGGVYAQRFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCWGQGTMVTVSS,0.0,0,jain2017_pnas
mepolizumab,QVTLRESGPALVKPTQTLTLTCTVSVHWVRQPPGKGLEWLGVDYNSALMSRLSISKDTSRNQVVLTMTNMDPVDTATYYCWGRGTPVTVSS,0.0,0,jain2017_pnas
mogamulizumab,EVQLVESGGDLVQPGRSLRLSCAASMSWVRQAPGKGLEWVATYYPDSVKGRFTISRDNAKNSLYLQMNSLRVEDTALYYCWGQGTLVTVSS,0.0,0,jain2017_pnas
motavizumab,QVTLRESGPALVKPTQTLTLTCTFSVGWIRQPPGKALEWLADHYNPSLKDRLTISKDTSKNQVVLKVTNMDPADTATYYCWGQGTTVTVSS,,1,jain2017_pnas
muromonab,QVQLQQSGAELARPGASVKMSCKASMHWVKQRPGQGLEWIGYNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCWGQGTTLTVSS,0.0,0,jain2017_pnas
natalizumab,QVQLVQSGAEVKKPGASVKVSCKASIHWVRQAPGQRLEWMGRKYDPKFQGRVTITADTSASTAYMELSSLRSEDTAVYYCWGQGTLVTVSS,0.0,0,jain2017_pnas
necitumumab,QVQLQESGPGLVKPSQTLSLTCTVSWSWIRQPPGKGLEWIGYDYNPSLKSRVTMSVDTSKNQFSLKVNSVTAADTAVYYCWGQGTLVTVSS,0.0,0,jain2017_pnas
nimotuzumab,QVQLQQSGAEVKKPGSSVKVSCKASIYWVRQAPGQGLEWIGGNFNEKFKTRVTITADESSTTAYMELSSLRSEDTAFYFCWGQGTTVTVSS,0.0,0,jain2017_pnas
nivolumab,QVQLVESGGGVVQPGRSLRLDCKASMHWVRQAPGKGLEWVAVYYADSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCWGQGTLVTVSS,0.0,0,jain2017_pnas
obinutuzumab,QVQLVQSGAEVKKPGSSVKVSCKASINWVRQAPGQGLEWMGRDYNGKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCWGQGTLVTVSS,0.0,0,jain2017_pnas
ocrelizumab,EVQLVESGGGLVQPGGSLRLSCAASMHWVRQAPGKGLEWVGASYNQKFKGRFTISVDKSKNTLYLQMNSLRAEDTAVYYCWGQGTLVTVSS,0.0,0,jain2017_pnas
ofatumumab,EVQLVESGGGLVQPGRSLRLSCAASMHWVRQAPGKGLEWVSTGYADSVKGRFTISRDNAKKSLYLQMNSLRAEDTALYYCWGQGTTVTVSS,0.0,0,jain2017_pnas
olaratumab,QLQLQESGPGLVKPSETLSLTCTVSWGWLRQSPGKGLEWIGSYYNPSLRSRLTISVDTSKNQFSLMLSSVTAADTAVYYCWDQGTLVTVSS,0.0,0,jain2017_pnas
olokizumab,EVQLVESGGGLVQPGGSLRLSCAASMNWVRQAPGKGLEWVAQYYAESLEGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCWGQGTLVTVSS,0.0,0,jain2017_pnas
omalizumab,EVQLVESGGGLVQPGGSLRLSCAVSWNWIRQAPGKGLEWVASNYNPSLKGRITISRDDSKNTFYLQMNSLRAEDTAVYYCWGQGTLVTVSS,0.0,0,jain2017_pnas
onartuzumab,EVQLVESGGGLVQPGGSLRLSCAASLHWVRQAPGKGLEWVGMRFNPNFKDRFTISADTSKNTAYLQMNSLRAEDTAVYYCWGQGTLVTVSS,0.0,0,jain2017_pnas
otelixizumab,EVQLLESGGGLVQPGGSLRLSCAASMAWVRQAPGKGLEWVSTYYRDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCWGQGTLVTVSS,0.0,0,jain2017_pnas
otlertuzumab,EVQLVQSGAEVKKPGESLKISCKGSMNWVRQMPGKGLEWMGNTYNRKFKGQVTISADKSISTAYLQWSSLKASDTAMYYCWGQGTLVTVSS,0.0,0,jain2017_pnas
ozanezumab,QVQLVQSGAEVKKPGASVKVSCKASMHWVRQAPGQGLEWIGNNYNEKFKSKATMTRDTSTSTAYMELSSLRSEDTAVYYCWGQGTLVTVSS,,3,jain2017_pnas
palivizumab,QVTLRESGPALVKPTQTLTLTCTFSVGWIRQPPGKALEWLADDYNPSLKSRLTISKDTSKNQVVLKVTNMDPADTATYYCWGAGTTVTVSS,0.0,0,jain2017_pnas
panitumumab,QVQLQESGPGLVKPSETLSLTCTVSWTWIRQSPGKGLEWIGHNYNPSLKSRLTISIDTSKTQFSLKLSSVTAADTAIYYCWGQGTMVTVSS,0.0,0,jain2017_pnas
panobacumab,EEQVVESGGGFVQPGGSLRLSCAASMHWVRQAPGKGLVWVSRYYADSVKGRFTISRDNARNTLYLQMNSLRAEDTAVYYCWGQGTMVTVSS,0.0,0,jain2017_pnas
parsatuzumab,EVQLVESGGGLVQPGGSLRLSCAASMNWVRQAPGKGLEWVGDHYNQKFKGRFTISRDKSKNTAYLQMNSLRAEDTAVYYCWGQGTLVTVSS,1.0,6,jain2017_pnas
patritumab,QVQLQQWGAGLLKPSETLSLTCAVYWSWIRQPPGKGLEWIGENYNPSLKSRVTISVETSKNQFSLKLSSVTAADTAVYYCWGRGTLVTVSS,1.0,4,jain2017_pnas
pembrolizumab,QVQLVQSGVEVKKPGASVKVSCKASMYWVRQAPGQGLEWMGGNFNEKFKNRVTLTTDSSTTTAYMELKSLQFDDTAVYYCWGQGTTVTVSS,0.0,0,jain2017_pnas
pertuzumab,EVQLVESGGGLVQPGGSLRLSCAASMDWVRQAPGKGLEWVADIYNQRFKGRFTLSVDRSKNTLYLQMNSLRAEDTAVYYCYWGQGTLVTVS,0.0,0,jain2017_pnas
pinatuzumab,EVQLVESGGGLVQPGGSLRLSCAASMNWVRQAPGKGLEWVGRNYSGKFKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCWGQGTLVTVSS,0.0,0,jain2017_pnas
polatuzumab,EVQLVESGGGLVQPGGSLRLSCAASIEWVRQAPGKGLEWIGENYNEIFKGRATFSADTSKNTAYLQMNSLRAEDTAVYYCWGQGTLVTVSS,0.0,0,jain2017_pnas
ponezumab,QVQLVQSGAEVKKPGASVKVSCKASIHWVRQAPGQGLEWMGRKYAPRLQDRVTMTRDTSTSTVYMELSSLRSEDTAVYYCWGQGTTVTVSS,1.0,4,jain2017_pnas
radretumab,EVQLLESGGGLVQPGGSLRLSCAASMSWVRQAPGKGLEWVSSYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCWGQGTLVTVSS,0.0,0,jain2017_pnas
ramucirumab,EVQLVQSGGGLVKPGGSLRLSCAASMNWVRQAPGKGLEWVSSYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCWGQGTMVTVSS,0.0,0,jain2017_pnas
ranibizumab,EVQLVESGGGLVQPGGSLRLSCAASMNWVRQAPGKGLEWVGWTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCWGQGTLVTVSS,,1,jain2017_pnas
reslizumab,EVQLVESGGGLVQPGGSLRLSCAVSVNWIRQAPGKGLEWVGLDYNSAIKSRFTISRDTSKSTVYLQMNSLRAEDTAVYYCWGQGTLVTVSS,0.0,0,jain2017_pnas
rilotumumab,QVQLQESGPGLVKPSETLSLTCTVSWSWIRQPPGKGLEWIGYNYNPSLKSRVTISVDTSKNQFSLKLNSVTAADTAVYYCWGQGTLVTVSS,0.0,0,jain2017_pnas
rituximab,QVQLQQPGAELVKPGASVKMSCKASMHWVKQTPGRGLEWIGASYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCWGAGTTVTVSA,0.0,0,jain2017_pnas
robatumumab,EVQLVQSGGGLVKPGGSLRLSCAASMHWVRQAPGKGLEWISVYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCWGQGTTVTVSS,1.0,4,jain2017_pnas
romosozumab,EVQLVQSGAEVKKPGASVKVSCKASMHWVRQAPGQGLEWMGEGYNQKFKGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCWGQGTTVTVSS,0.0,0,jain2017_pnas
sarilumab,EVQLVESGGGLVQPGRSLRLSCAASMHWVRQAPGKGLEWVSGGYADSVKGRFTISRDNAENSLFLQMNGLRAEDTALYYCWGQGTMVTVSS,0.0,0,jain2017_pnas
secukinumab,EVQLVESGGGLVQPGGSLRLSCAASMNWVRQAPGKGLEWVAAYYVGSVKGRFTISRDNAKNSLYLQMNSLRVEDTAVYYCWGRGTLVTVSS,0.0,0,jain2017_pnas
seribantumab,EVQLLESGGGLVQPGGSLRLSCAASMAWVRQAPGKGLEWVSSLYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCWGQGTLVTVSS,0.0,0,jain2017_pnas
sifalimumab,QVQLVQSGAEVKKPGASVKVSCKASISWVRQAPGQGLEWMGWNYAQKFQGRVTMTTDTSTSTAYLELRSLRSDDTAVYYCWGQGTLVTVSS,,3,jain2017_pnas
siltuximab,EVQLVESGGKLLKPGGSLKLSCAASMSWFRQSPEKRLEWVAEYYPDTVTGRFTISRDNAKNTLYLEMSSLRSEDTAMYYCWGQGTSVTVSS,0.0,0,jain2017_pnas
simtuzumab,QVQLVQSGAEVKKPGASVKVSCKASIEWVRQAPGQGLEWIGVNYNEKFKGRATITADKSTSTAYMELSSLRSEDTAVYFCWGQGTTVTVSS,1.0,6,jain2017_pnas
sirukumab,EVQLVESGGGLVQPGGSLRLSCAASMSWVRQAPGKGLEWVAKYYSDTVTGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCWGQGTTVTVSS,1.0,5,jain2017_pnas
tabalumab,QVQLQQWGAGLLKPSETLSLTCAVYWSWIRQPPGKGLEWIGENYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCWGQGTLVTVSS,0.0,0,jain2017_pnas
tanezumab,QVQLQESGPGLVKPSETLSLTCTVSLNWIRQPPGKGLEWIGIDYNSAVKSRVTISKDTSKNQFSLKLSSVTAADTAVYYCWGQGTLVTVSS,,1,jain2017_pnas
teplizumab,QVQLVQSGGGVVQPGRSLRLSCKASMHWVRQAPGKGLEWIGYNYNQKVKDRFTISRDNSKNTAFLQMDSLRPEDTGVYFCWGQGTPVTVSS,,2,jain2017_pnas
tigatuzumab,EVQLVESGGGLVQPGGSLRLSCAASMSWVRQAPGKGLEWVATYYPDSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCWGQGTLVTVSS,0.0,0,jain2017_pnas
tildrakizumab,QVQLVQSGAEVKKPGASVKVSCKASMTWVRQAPGQGLEWMGQDYNEKFEGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCWGQGTLVTVSS,0.0,0,jain2017_pnas
tocilizumab,QVQLQESGPGLVRPSQTLSLTCTVSWSWVRQPPGRGLEWIGYTYNPSLKSRVTMLRDTSKNQFSLRLSSVTAADTAVYYCWGQGSLVTVSS,0.0,0,jain2017_pnas
tovetumab,QVQLVESGGGLVKPGGSLRLSCAASMNWIRQAPGKGLEWVSYYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCWGQGTTVTVSS,0.0,0,jain2017_pnas
tralokinumab,QVQLVQSGAEVKKPGASVKVSCKASLSWVRQAPGQGLEWMGWNYGQEFQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCWGRGTLVTVSS,0.0,0,jain2017_pnas
trastuzumab,EVQLVESGGGLVQPGGSLRLSCAASIHWVRQAPGKGLEWVARRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCWGQGTLVTVSS,0.0,0,jain2017_pnas
tremelimumab,QVQLVESGGGVVQPGRSLRLSCAASMHWVRQAPGKGLEWVAVYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCWGQGTTVTVSS,0.0,0,jain2017_pnas
urelumab,QVQLQQWGAGLLKPSETLSLTCAVYWSWIRQSPEKGLEWIGETYNPSLESRVTISVDTSKNQFSLKLSSVTAADTAVYYCWGRGTLVTVSS,0.0,0,jain2017_pnas
ustekinumab,EVQLVQSGAEVKKPGESLKISCKGSLGWVRQMPGKGLDWIGIRYSPSFQGQVTMSVDKSITTAYLQWNSLKASDTAMYYCWGQGTLVTVSS,,3,jain2017_pnas
vedolizumab,QVQLVQSGAEVKKPGASVKVSCKGSMHWVRQAPGQRLEWIGENYNQKFKGRVTLTVDISASTAYMELSSLRSEDTAVYYCWGQGTLVTVSS,0.0,0,jain2017_pnas
veltuzumab,QVQLQQSGAEVKKPGSSVKVSCKASMHWVKQAPGQGLEWIGASYNQKFKGKATLTADESTNTAYMELSSLRSEDTAFYYCWGQGTTVTVSS,0.0,0,jain2017_pnas
visilizumab,QVQLVQSGAEVKKPGASVKVSCKASMHWVRQAPGQGLEWMGYHYNQKLKDKATLTADKSASTAYMELSSLRSEDTAVYYCWGQGTLVTVSS,,3,jain2017_pnas
zalutumumab,QVQLVESGGGVVQPGRSLRLSCAASMHWVRQAPGKGLEWVAVYYGDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCWGQGTLVTVSS,,1,jain2017_pnas
zanolimumab,QVQLQQWGAGLLKPSETLSLTCAVYWSWIRQPPGKGLEWIGENYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCWGQGTLVTVSS,0.0,0,jain2017_pnas
